Baseline risk factors associated with immune related adverse events and atezolizumab.

Madjar, Katrin; Mohindra, Rajat; Durán-Pacheco, Gonzalo; Rasul, Rashad; Essioux, Laurent; Maiya, Vidya; Chandler, G Scott

Madjar, Katrin; Mohindra, Rajat; Durán-Pacheco, Gonzalo; Rasul, Rashad; Essioux, Laurent; Maiya, Vidya; Chandler, G Scott.

Afiliação

Madjar K; Product Development (PD), F. Hoffmann-La Roche, Basel, Switzerland.
Mohindra R; Product Development (PD), F. Hoffmann-La Roche, Basel, Switzerland.
Durán-Pacheco G; Product Development (PD), F. Hoffmann-La Roche, Basel, Switzerland.
Rasul R; Statistical Programming and Technology, Bristol Myers Squibb, Basel, Switzerland.
Essioux L; Product Development (PD), F. Hoffmann-La Roche, Basel, Switzerland.
Maiya V; Product Development (PD), Genentech, Inc., South San Francisco, CA, United States.
Chandler GS; Product Development (PD), F. Hoffmann-La Roche, Basel, Switzerland.

Front Oncol ; 13: 1138305, 2023.

Article em En | MEDLINE | ID: mdl-36925916

Palavras-chave

anti-PDL1; baseline risk factors; immune checkpoint inhibitor; immune-related adverse event; toxicity

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Risk_factors_studies / Systematic_reviews Idioma: En Revista: Front Oncol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Suíça

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google